These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 16524321)

  • 1. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
    Hartmann JT; Lipp HP
    Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide: four decades of development of a topoisomerase II inhibitor.
    Hande KR
    Eur J Cancer; 1998 Sep; 34(10):1514-21. PubMed ID: 9893622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Topoisomerase inhibitors developing in Japan].
    Furue H
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
    Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
    Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of topoisomerase-interactive drugs.
    Muggia FM; Burris HA
    Adv Pharmacol; 1994; 29B():1-31. PubMed ID: 8996599
    [No Abstract]   [Full Text] [Related]  

  • 10. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
    Sinha BK
    Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of camptothecin analogs in childhood cancers.
    Bomgaars L; Berg SL; Blaney SM
    Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
    Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of the topoisomerase I inhibitors.
    Seiter K
    Expert Opin Drug Saf; 2005 Jan; 4(1):45-53. PubMed ID: 15709897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacology of camptothecin and its derivatives].
    Rivory LP; Robert J
    Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
    Demarquay D; Coulomb H; Huchet M; Lesueur-Ginot L; Camara J; Lavergne O; Bigg D
    Ann N Y Acad Sci; 2000; 922():301-2. PubMed ID: 11193906
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical pharmacology of topoisomerase I inhibitors.
    Abang AM
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irinotecan pharmacokinetics].
    Chabot GG; Robert J; Lokiec F; Canal P
    Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.